Edition:
India

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

72.99USD
12:06am IST
Change (% chg)

$0.27 (+0.37%)
Prev Close
$72.72
Open
$73.47
Day's High
$73.90
Day's Low
$72.38
Volume
41,740
Avg. Vol
190,510
52-wk High
$91.75
52-wk Low
$47.11

Latest Key Developments (Source: Significant Developments)

Spark Therapeutics reports Q3 loss per share $1.90
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics Inc reports third quarter 2017 financial results and recent business progress.Q3 loss per share $1.90.Q3 earnings per share view $-1.81 -- Thomson Reuters I/B/E/S.  Full Article

Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B.Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer.Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001.Spark Therapeutics - ‍Subject to terms of amendment, Spark Therapeutics will receive from pfizer an initial $10 million cash payment​.Spark Therapeutics Inc - Will enroll up to five additional participants in current phase 1/2 clinical trial​.Spark - ‍Subject to amendment, to receive from Pfizer up to additional $15 million in potential milestone payments upon completion of transition activities​.Spark Therapeutics - ‍Activities outlined in amended agreement will occur parallel to Pfizer's ongoing preparation to assume responsibility for SPK-9001.  Full Article

Spark Therapeutics says NASDAQ halts trading of its common stock
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Spark Therapeutics Inc : :Spark Therapeutics (once) trading of stock halted as FDA advisory committee reviews investigational gene therapy.Spark Therapeutics Inc - U.S. ‍FDA's cellular, tissue and gene therapies advisory committee is meeting today to review LUXTURNA (voretigene neparvovec)​.Spark Therapeutics Inc - ‍LUXTURNA is under priority review with FDA, with an assigned prescription drug user fee act (PDUFA) date of jan. 12, 2018​.  Full Article

Spark Therapeutics Q2 loss per share $1.04
Wednesday, 10 Aug 2016 

Spark Therapeutics Inc : Q2 loss per share $1.04 . Spark therapeutics reports second quarter 2016 financial results and recent business highlights . Q2 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S . Q2 revenue $1.3 million versus $1.3 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Spark says announces publication of positive follow-up data from phase 1 trial of voretigene neparvovec in The Lancet
Friday, 1 Jul 2016 

Spark Therapeutics Inc : Says has initiated a rolling submission of bla with fda on voretigene neparvovec .Spark therapeutics announces publication of positive follow-up data from phase 1 trial of voretigene neparvovec in the lancet.  Full Article

Spark Therapeutics public offering of 3.50 mln shares priced at $45/shr
Wednesday, 15 Jun 2016 

Spark Therapeutics Inc : Spark Therapeutics announces pricing of public offering .Says public offering of 3.50 million common shares priced at $45.00per share.  Full Article

Spark Therapeutics files for potential mixed shelf offering
Tuesday, 14 Jun 2016 

Spark Therapeutics Inc :Files for potential mixed shelf offering; size not disclosed - SEC filing.  Full Article

Spark Therapeutics says selling stockholders may sell up to 265,000 shares
Saturday, 4 Jun 2016 

Spark Therapeutics Inc :Files to say selling stockholders may sell up to 265,000 shares of co's common stock.  Full Article

Spark Therapeutics, Inc announces acquisition of Genable Technologies
Monday, 7 Mar 2016 

Spark Therapeutics, Inc:Announces acquisition of genable technologies.Says consideration paid to genable shareholders consisted of $6 million in cash and 265,000 shares of Spark common stock.Says additional financial terms were not disclosed.  Full Article

Spark Therapeutics announces launch of public offering
Tuesday, 15 Dec 2015 

Spark Therapeutics:Announces launch of public offering.Says commenced an underwritten public offering of 3 million shares of its common stock.Offering consists of 2 million shares being offered by Spark and 1 million shares being offered by children's hospital of Philadelphia foundation.  Full Article

BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

* Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B